The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan: A Phase I, Multiple-Center, Open-Label Study Following Multiple Daily Oral Doses of Balovaptan in Subjects With Moderate Hepatic Impairment and Healthy Subjects With Normal Hepatic Function
Latest Information Update: 01 Nov 2021
At a glance
- Drugs Balovaptan (Primary)
- Indications Pervasive child development disorders
- Focus Pharmacokinetics
- Sponsors Roche
Most Recent Events
- 26 Oct 2021 Status changed from suspended to withdrawn prior to enrolment.
- 16 Apr 2021 Status changed from not yet recruiting to suspended due to stopping of the Autism Spectrum Disorder program with balovatpan, the study drug
- 13 Aug 2020 Planned End Date changed from 13 Oct 2020 to 13 Oct 2022.